The University of Western Australia
Dr Matthew Piggott
Senior Lecturer
Contact details
| Address | Chemistry The University of Western Australia (M310) 35 Stirling Highway CRAWLEY WA 6009 Australia |
|---|---|
| Phone | 6488 3170 |
| Fax | 6488 1005 |
| matthew.piggott@uwa.edu.au |
Location
Room 329, Molecular and Chemical Sciences Building, Crawley campus
Biography
Dr Matthew Piggott completed his BSc (Hons 1) and PhD at The University of Western Australia. After postdoctoral stints at The Australian National University, and Boston College, he took up a lecturing position at the ANU in the Department of Chemistry. In 2005 Matthew moved to the School of Biomedical, Biomolecular and Chemical Sciences at UWA.
Key research
- Our group’s research primarily involves the rational design and synthesis of biologically active compounds, either as drug candidates or as probes to gain insight into complicated biological systems. Our expertise is in synthetic organic chemistry and an overriding aim is to develop concise and efficient syntheses so that useful quantities of end-products and intermediates can be provided for biological evaluation by our collaborators.
- Another area of interest is the design and synthesis of large, novel polycyclic aromatic compounds with potential materials and supramolecular applications.
Major research interests
- Bioactive natural product synthesis
- Burkitt's lymphoma
- Chemical biology
- Medicinal chemistry
- Neuroscience: Parkinson's disease
- Synthetic organic chemistry
- Theoretically interesting compounds
Qualifications
BSc PhD W.Aust.
Publications
“Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride”, Matthew J. McIldowie, Michael N. Gandy, Brian W. Skelton, Jonathan M. Brotchie, George A. Koutsantonis, Mark A. Spackman and Matthew J. Piggott. J. Pharm. Sci., in press.
“Focus on phospholysine and phosphoarginine”, Besant P.G., Attwood P.V. and Piggott M.J., Curr. Prot. Pept. Sci., accepted.
“Synthesis of Kalasinamide, a Putative Plant Phototoxin”, Michael N. Gandy and Matthew J. Piggott, J. Nat. Prod., 2008, 71, 866–868.
“Insights into the mechanism and regulation of pyruvate carboxylase by characterisation of a biotin-deficient mutant of the Bacillus thermodenitrificans enzyme”, Abdussalam Adina-Zada, Sarawut Jitrapakdee, Kathy H. Surinya, Matthew McIldowie, Matthew J. Piggott, Wallace W. Cleland, John C. Wallace and Paul V. Attwood, Int. J. Biochem. Cell Biol., 2008, 40, 1743–1752.
“Analysis of trimethyl carboxyphosphate by GC–MS”, Matthew J. McIldowie, Paul V. Attwood, Anthony Reeder and Matthew J. Piggott, Anal. Biochem., 2008, 376, 283–285.
“Progress toward a Rationally Designed, Chemically Powered Rotary Molecular Motor”, T. Ross Kelly, Xiaolu Cai, Fehmi Damkaci, Sreeletha B. Panicker, Bin Tu, Simon M. Bushell, Ivan Cornella, Matthew J. Piggott, Richard Salives, Marta Cavero, Yajun Zhao, Serge Jasmin, J. Am. Chem. Soc., 2007, 129, 376–386.
“Focus on phosphohistidine”, P.V. Attwood, M. J. Piggott, X. L. Zu and P. G. Besant, Amino Acids, 2007, 32, 145–156.
“Synthesis of 5,8-dimethoxynaphtho[2,3-c]furan-4(9H)-one”, Matthew J. Piggott and Dieter Wege, Tetrahedron, 2006, 62, 3550–3556.
“Naphtho[2,3-c]furan-4,9-diones and related compounds: theoretically interesting and bioactive natural and synthetic products”, Matthew J. Piggott, Tetrahedron, 2005, 61, 9929–9954.
“Crystal Structure of 1-Methyl-5,8-dihydroxynaphtho[2,3-c]furan-4,9-dione”, Brian W. Skelton and Matthew J. Piggott, Aust. J. Chem. 2005, 58, 600–602.
“The Synthesis of 5-Hydroxy-3-methylnaphtho[2,3-clfuran-4,9-dione and 5,8-Dihydroxy-1-methylnaphtho[2,3-c]furan-4,9-dione”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 2003, 56, 691–702.
“The Synthesis of Ventilone A”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 2000, 53, 749–754.
“Some Cycloaddition Reactions of 5,8-Dimethoxynaphtho[2,3-c]furan-4,9-dione”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 1998, 51, 819–824.
“Western Australian Sandalwood Oil: Extraction by Different Techniques and Variations of the Major Components in Different Sections of a Single Tree”, Emilio L. Ghisalberti, Matthew J. Piggott, and Robert D. Trengove, Flavour and Fragrance J., 1997, 12, 43–46.
Recent conference presentations and posters
“Redesigning the designer drug ecstasy”, MJ Piggott, JM Brotchie, MN Gandy, J Gordon, TH Johnston, KD Lewis, M Martin-Iverson, MJ McIldowie, PTH Nguyen, B van Doorn, S Thiele, D Tindiglia, K Wagg, AM Wasik, RACI OPC, Adelaide, 2007 (oral).
“UWA-0101, extends the duration and quality of anti-parkinsonian benefit provided by L-DOPA action in the MPTP-lesioned primate model of Parkinson’s disease”, MJ Piggott, MJ McIldowie, S Thiele, TH Johnston, SH Fox, JM Brotchie, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2007.
“Effects of MDMA (“ecstasy”), PMA and two new MDMA analogues, developed as potential therapies for LDOPA-induced dyskinesia, on prepulse inhibition of the startle reflex in rats”, D Tindiglia, MJ Piggott, KD Lewis, MN Gandy, MJ McIldowie, MT Martin-Iverson, Canadian College of Neuropsychopharmacology annual Meeting, Banff, Canada, 2007.
“Neurotoxicological characterization of MDMA-analogs in vitro: Implications for the symptomatic treatment of PD”, D Salomonczyk, M McIldowie, JM Brotchie, M Piggott, & JE Nash, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2007.
“a-Substituted analogues of MDMA (‘ecstasy’) with potential for treating Parkinson’s disease”, MJ Piggott, JM Brotchie, MN Gandy, TH Johnston, KD Lewis, M Martin-Iverson, MJ McIldowie, PTH Nguyen, B van Doorn, D Tindiglia, K Wagg, Drug design amongst the vines, Hunter Valley, 2006 (oral).
“Characterisation of the Neurotoxicity of MDMA Analogues in a Cell Culture Model Of Parkinson’s Disease: Implications For Symptomatic Therapies”, DS Salomoncyzk, JM Brotchie, M McIldowie, M Piggott, JE Nash, Society for Neuroscience Annual Meeting, Atlanta, GA, USA, 2006.
“An alpha-substituted MDMA ("ecstasy") analogue, ATK-0101, extends the duration of L-DOPA action in the MPTP-lesioned primate model of Parkinson's disease” TH Johnston, SH Fox, SH, MJ McIldowie, MJ Piggott, JM Brotchie. Movement Disorders 21: S642-S642, Suppl. 15, 2006.
“ATK-0091, and related alpha-substituted analogues of MDMA ("Ecstasy"), may have potential in the treatment of Parkinson's disease” MJ Piggott, K Wagg, T Johnston, J Lee, J Gomez-Ramirez, JM Brotchie. Movement Disorders 19: S265-S265, Suppl. 9, 2004.
“ATK-0001, an á-substituted analogue of MDMA (‘ecstasy’) has potential to reduce L-DOPA induced dyskinesia in Parkinson’s disease”, MJ Piggott, K Wagg, TH Johnston, JM Brotchie, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2004.
“Analogues of MDMA as potential therapeutic agents for the treatment of Parkinson’s disease”, MJ Piggott, K Wagg, TH Johnston, JM Brotchie, 20th RACI Organic Chemistry Conference, Cairns, Australia, 2004; Annual RACI NSW one-day symposium, Sydney, Australia, 2004; Making Connections with Parkinson’s Disease, Multiple Sclerosis and Motor Neurone Disease, Sydney, Australia, 2004.
“Studies toward a continuously rotating unimolecular motor” M Cavero, Y Zhao, J Beierle, I Cornella, R Salives, MJ Piggott, TR Kelly, Abstracts of Papers of the American Chemical Society 224: U192-U192, Part 2. 2002.
“Focus on phospholysine and phosphoarginine”, Besant P.G., Attwood P.V. and Piggott M.J., Curr. Prot. Pept. Sci., accepted.
“Synthesis of Kalasinamide, a Putative Plant Phototoxin”, Michael N. Gandy and Matthew J. Piggott, J. Nat. Prod., 2008, 71, 866–868.
“Insights into the mechanism and regulation of pyruvate carboxylase by characterisation of a biotin-deficient mutant of the Bacillus thermodenitrificans enzyme”, Abdussalam Adina-Zada, Sarawut Jitrapakdee, Kathy H. Surinya, Matthew McIldowie, Matthew J. Piggott, Wallace W. Cleland, John C. Wallace and Paul V. Attwood, Int. J. Biochem. Cell Biol., 2008, 40, 1743–1752.
“Analysis of trimethyl carboxyphosphate by GC–MS”, Matthew J. McIldowie, Paul V. Attwood, Anthony Reeder and Matthew J. Piggott, Anal. Biochem., 2008, 376, 283–285.
“Progress toward a Rationally Designed, Chemically Powered Rotary Molecular Motor”, T. Ross Kelly, Xiaolu Cai, Fehmi Damkaci, Sreeletha B. Panicker, Bin Tu, Simon M. Bushell, Ivan Cornella, Matthew J. Piggott, Richard Salives, Marta Cavero, Yajun Zhao, Serge Jasmin, J. Am. Chem. Soc., 2007, 129, 376–386.
“Focus on phosphohistidine”, P.V. Attwood, M. J. Piggott, X. L. Zu and P. G. Besant, Amino Acids, 2007, 32, 145–156.
“Synthesis of 5,8-dimethoxynaphtho[2,3-c]furan-4(9H)-one”, Matthew J. Piggott and Dieter Wege, Tetrahedron, 2006, 62, 3550–3556.
“Naphtho[2,3-c]furan-4,9-diones and related compounds: theoretically interesting and bioactive natural and synthetic products”, Matthew J. Piggott, Tetrahedron, 2005, 61, 9929–9954.
“Crystal Structure of 1-Methyl-5,8-dihydroxynaphtho[2,3-c]furan-4,9-dione”, Brian W. Skelton and Matthew J. Piggott, Aust. J. Chem. 2005, 58, 600–602.
“The Synthesis of 5-Hydroxy-3-methylnaphtho[2,3-clfuran-4,9-dione and 5,8-Dihydroxy-1-methylnaphtho[2,3-c]furan-4,9-dione”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 2003, 56, 691–702.
“The Synthesis of Ventilone A”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 2000, 53, 749–754.
“Some Cycloaddition Reactions of 5,8-Dimethoxynaphtho[2,3-c]furan-4,9-dione”, Matthew J. Piggott and Dieter Wege, Aust. J. Chem., 1998, 51, 819–824.
“Western Australian Sandalwood Oil: Extraction by Different Techniques and Variations of the Major Components in Different Sections of a Single Tree”, Emilio L. Ghisalberti, Matthew J. Piggott, and Robert D. Trengove, Flavour and Fragrance J., 1997, 12, 43–46.
Recent conference presentations and posters
“Redesigning the designer drug ecstasy”, MJ Piggott, JM Brotchie, MN Gandy, J Gordon, TH Johnston, KD Lewis, M Martin-Iverson, MJ McIldowie, PTH Nguyen, B van Doorn, S Thiele, D Tindiglia, K Wagg, AM Wasik, RACI OPC, Adelaide, 2007 (oral).
“UWA-0101, extends the duration and quality of anti-parkinsonian benefit provided by L-DOPA action in the MPTP-lesioned primate model of Parkinson’s disease”, MJ Piggott, MJ McIldowie, S Thiele, TH Johnston, SH Fox, JM Brotchie, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2007.
“Effects of MDMA (“ecstasy”), PMA and two new MDMA analogues, developed as potential therapies for LDOPA-induced dyskinesia, on prepulse inhibition of the startle reflex in rats”, D Tindiglia, MJ Piggott, KD Lewis, MN Gandy, MJ McIldowie, MT Martin-Iverson, Canadian College of Neuropsychopharmacology annual Meeting, Banff, Canada, 2007.
“Neurotoxicological characterization of MDMA-analogs in vitro: Implications for the symptomatic treatment of PD”, D Salomonczyk, M McIldowie, JM Brotchie, M Piggott, & JE Nash, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2007.
“a-Substituted analogues of MDMA (‘ecstasy’) with potential for treating Parkinson’s disease”, MJ Piggott, JM Brotchie, MN Gandy, TH Johnston, KD Lewis, M Martin-Iverson, MJ McIldowie, PTH Nguyen, B van Doorn, D Tindiglia, K Wagg, Drug design amongst the vines, Hunter Valley, 2006 (oral).
“Characterisation of the Neurotoxicity of MDMA Analogues in a Cell Culture Model Of Parkinson’s Disease: Implications For Symptomatic Therapies”, DS Salomoncyzk, JM Brotchie, M McIldowie, M Piggott, JE Nash, Society for Neuroscience Annual Meeting, Atlanta, GA, USA, 2006.
“An alpha-substituted MDMA ("ecstasy") analogue, ATK-0101, extends the duration of L-DOPA action in the MPTP-lesioned primate model of Parkinson's disease” TH Johnston, SH Fox, SH, MJ McIldowie, MJ Piggott, JM Brotchie. Movement Disorders 21: S642-S642, Suppl. 15, 2006.
“ATK-0091, and related alpha-substituted analogues of MDMA ("Ecstasy"), may have potential in the treatment of Parkinson's disease” MJ Piggott, K Wagg, T Johnston, J Lee, J Gomez-Ramirez, JM Brotchie. Movement Disorders 19: S265-S265, Suppl. 9, 2004.
“ATK-0001, an á-substituted analogue of MDMA (‘ecstasy’) has potential to reduce L-DOPA induced dyskinesia in Parkinson’s disease”, MJ Piggott, K Wagg, TH Johnston, JM Brotchie, Society for Neuroscience Annual Meeting, San Diego, CA, USA, 2004.
“Analogues of MDMA as potential therapeutic agents for the treatment of Parkinson’s disease”, MJ Piggott, K Wagg, TH Johnston, JM Brotchie, 20th RACI Organic Chemistry Conference, Cairns, Australia, 2004; Annual RACI NSW one-day symposium, Sydney, Australia, 2004; Making Connections with Parkinson’s Disease, Multiple Sclerosis and Motor Neurone Disease, Sydney, Australia, 2004.
“Studies toward a continuously rotating unimolecular motor” M Cavero, Y Zhao, J Beierle, I Cornella, R Salives, MJ Piggott, TR Kelly, Abstracts of Papers of the American Chemical Society 224: U192-U192, Part 2. 2002.
Roles, responsibilities and expertise
Expertise:
Organic Synthetic Chemistry
Medicinal Chemistry
Parkinson's disease
Chair, Chemistry Safety Committee
Chair, UWA Mutagens and Carcinogens Committee
Organic Synthetic Chemistry
Medicinal Chemistry
Parkinson's disease
Chair, Chemistry Safety Committee
Chair, UWA Mutagens and Carcinogens Committee
Funding received
The Brain Foundation
Ada Bartholomew Medical Research Trust
Atuka Ltd
ARC LIEF
Ada Bartholomew Medical Research Trust
Atuka Ltd
ARC LIEF
Industrial relevance
Drug Discovery
Memberships
Royal Australian Chemical Institute
American Chemical Society
American Chemical Society
Honours and awards
The 2008 Royal Australian Chemical Institute (RACI), Organic Division Lectureship for Recently Appointed Staff
Previous positions
Lecturer, The Australian National University
Teaching
CHEM1102 Organic Chemistry
CHEM2211 Synthetic and Materials Chemistry
CHEM3305 Biological Chemistry
CHEM3312 Medicinal Chemistry
CHEM2211 Synthetic and Materials Chemistry
CHEM3305 Biological Chemistry
CHEM3312 Medicinal Chemistry
Current external positions
Management Committee, "Chemistry in Australia", the magazine of the Royal Australian Chemical Institute.
Compiler "Research" column in Chem. in Aust. (Formerly "Highlights of Australian Chemistry".
Compiler "Research" column in Chem. in Aust. (Formerly "Highlights of Australian Chemistry".
Useful links
http://www.researcherid.com/rid/A-3251-2008
Current projects
Research Students
Michael Gandy (PhD scholar, commenced 2006)
Redesigning the designer drug ‘ecstasy’: analogues of MDMA for the treatment of Parkinson’s disease and Burkitt’s lymphoma
Katie Punch (PhD scholar, commenced mid-2006)
Total synthesis of monosporascone and related natural products
Shin Mukai (PhD scholar, commenced 2007)
Stable analogues of phosphohistidine
Hung (Blake) Nguyen (PhD scholar, commenced mid-2007)
Parkinson’s disease medicinal chemistry
Jesse Parkin-Gibbs (PhD scholar, commenced 2009)
Total synthesis of biologically active alkaloids
Erik Jan Lindeboom (Occupational Trainee)
An improved, large scale synthesis of Leadfluor-1.
David Osbourne (Honours Student)
Polyacenes as bridging ligands for photoactive metal complexes.
Collaborators
Dr Jonathan Brotchie, University Health Network, Toronto Western Research Institute, Canada
Professor John Gordon, Birmingham University, UK
Dr Joanne Nash, University of Toronto, Canada
A/Prof Mathew Martin Iverson, UWA
A/Prof Paul Attwood, UWA
Dr Paul Besant, UWA
A/Prof George Koutsantonis, UWA
For more details on any of these areas of research please email Matthew.
Michael Gandy (PhD scholar, commenced 2006)
Redesigning the designer drug ‘ecstasy’: analogues of MDMA for the treatment of Parkinson’s disease and Burkitt’s lymphoma
Katie Punch (PhD scholar, commenced mid-2006)
Total synthesis of monosporascone and related natural products
Shin Mukai (PhD scholar, commenced 2007)
Stable analogues of phosphohistidine
Hung (Blake) Nguyen (PhD scholar, commenced mid-2007)
Parkinson’s disease medicinal chemistry
Jesse Parkin-Gibbs (PhD scholar, commenced 2009)
Total synthesis of biologically active alkaloids
Erik Jan Lindeboom (Occupational Trainee)
An improved, large scale synthesis of Leadfluor-1.
David Osbourne (Honours Student)
Polyacenes as bridging ligands for photoactive metal complexes.
Collaborators
Dr Jonathan Brotchie, University Health Network, Toronto Western Research Institute, Canada
Professor John Gordon, Birmingham University, UK
Dr Joanne Nash, University of Toronto, Canada
A/Prof Mathew Martin Iverson, UWA
A/Prof Paul Attwood, UWA
Dr Paul Besant, UWA
A/Prof George Koutsantonis, UWA
For more details on any of these areas of research please email Matthew.
Research profile
